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Abstract 
30 patients were enrolled in a double blind study designed to determine the efficacy and 
subjective preferences in reducing deposit accumulation, both lipid and protein, between 
an in-eye cleaninglre-wetting drop and a control re-wetting drop while wearing silicone 
hydrogel contact lenses on a 30 day continuous wear schedule. The patients had 
previously worn these contact lenses on a continuous wear schedule for a minimum of 
two weeks prior to enrollment in this study, and were asked to determine their 
preferences based on comfort, vision, and contact lens cleanliness. 27 patients completed 
the study of two thirty day continuous wear periods. With regard to comfort, 55.56% 
preferred the control drops, 29.63% preferred the in-eye cleaninglre-wetting drops, and 
14.81% had no preference. With regard to vision 33.33% preferred the control drops, 
25.93% preferred the in-eye cleaninglre-wetting drops, and 40.74% had no preference. 
With regard to lens cleanliness 48.15% preferred the control drops, 25.93% preferred the 
in-eye cleaninglre-wetting drops, and the remaining 25.93% had no preference. 
Biomicroscopy results of contact lens wetting, deposits, and numbers of mucin balls were 
equivalent for the two drops. In-eye cleaninglre-wetting drops appear to be compatible 
with silicone hydrogel contact lenses worn on a continuous wear basis and are similar in 
performance to re-wetting drops. 
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Introduction 
Practitioners have long been concerned over the increased rate of ocular complications 
associated with hydrogel contact lenses worn on an extended or continuous wear basis. 
While problems such as corneal edema and neovascularization resulting from hypoxia 
have decreased with the advent of silicone hydrogel contact lenses, other findings, such 
as surface deposits, are still a concern I-'. 
Surface deposits may lead to decreased wettability of the contact lenses, decreased 
comfort, decreased visual acuity, and may potentially result in triggering an inflammatory 
response such as papillary conjunctivitis 2-3,9-1 I ,  13-14 . These findings could limit wear 
time, necessitate replacement of contact lenses more frequently, and perhaps lead to drop 
out from contact lens wear altogether lo. 
In-eye cleaninglre-wetting drops have been shown to be beneficial in HEMA-based 
contact lenses leading to fewer surface deposits, increased wettability, and increased 
patient comfort. These products utilize surfactants to reduce protein binding which 
increases both comfort and wettability l2>l5.  The purpose of this study was to determine if 
the use of an in-eye cleaninglre-wetting drop with continuous wear of silicone hydrogel 
contact lenses influences subjective performance and surface characteristics. The aims of 
the study were: 
(1) To determine if the use an in-eye cleaninglre-wetting drop offered better subjective 
comfort and visual performance in comparison to a simple re-wetting drop with 
continuous wear of the lenses; 
(2) To determine if there was a difference in the amount ancl type of surface deposits on 
the lenses when using stn in-eye cleaning/re-wetting drop versus a re-wetting drop; and, 
(3) To determine if there was a difference in surface wettability with the use of an in-eye 
cleaningre-wetting drop versus a re-wetting drop with continuous wear of the lenses. 
Methods 
The study was a randomized doubIe-blind cross-over design in which subjects wore 
silicone hydrogel contact lenses on a continuous wear basis during two phases. Subjects 
used in-eye cleaning/re-wetting drops and re-wetting drops for one month each. Thc 
subjects were asked to wear the lenses, on a continuous basis for up to one month and 
instill each masked-label drop three limes a day. 
The suibjects were evaluated at the following intervals: 
Dispensing visit 
Two weeks 
* One month 
Second dispensing visit 
Twowceks 
* One month 
Subjects were initially randomly dispensed either in-eye clcaninglre-wetting drops or re- 
wetting drops. Prior to dispense each subject completed a "wash-out" period of either 
spectacle Iens wear or daily disposable sot? contact lens wear for three days. Subjects 
were advised to not usc any lens care or Iens drops during wash-out periods. At the end 
of onc month (28 days +/- 3 days), the subjects once again underwent a three day "wash- 
out" period to ensure that experiences from Phase I did not influence Phase 11. Each, 
were then dispensed a new pair of Ienses and crossed-over to the second Iens drop for the 
second month long phase. 
For each phase, subjects returned on the 2sth day (+I- 3 days) at which time the lenses 
were removed and collected by the investigators. The lenses were sent to the CCLR in 
Waterloo, Ontario where they will be assessed for surface deposition. The individuals 
assessing lens surface deposition were also masked to the lens drops utilized with each 
lens. 
Subject Eligibility Criteria 
Inclusion Criteria 
Prior to consideration for this clinical investigation, each prospective subject must have 
met the following conditions: 
1. The subject must have no known ocular or systemic allergies which might interfere 
with contact lens wear. 
2. The subject must have no known systemic disease, or need for medication, which 
might interfere with contact lens wear, i.e. antihistamines. 
3. The subject must have normal eyes (no ocular medications or ocular infection of any 
type>- 
4. The subject must have a visual acuity best correctable to 20120 with spectacles for 
each eye. 
5. The subject must be spherically correctable to a distance visual acuity of 20130 or 
better for each eye. 
6. The subject must read and sign the Statement of Informed Consent and be provided 
with a copy of the form. 
7. The subject must appear and be willing to adhere to the instructions set forth in this 
clinical protocol. 
8. The subject, based on their knowledge, must NOT be pregnant or lactating at the time 
of enrollment. 
9. The subject, based on their knowledge, must NOT have an infectious disease (e.g., 
hepatitis, tuberculosis) or an immunosuppressive disease (e.g., HIV). 
10. The subject, based on their knowledge, must NOT be diabetic. 
11. The subject must have a contact lens prescription between +6.00 D Sph and 
-10.00 D Sph. 
12. The subject must be corrected to 20130 or better in each eye with the study contact 
lenses and satisfied with the vision and comfort of each lens. 
13. The subject must be an adapted wearer of silicone hydrogel contact lenses (minimum 
of two weeks of previous successful continuous wear prior to study enrollment). 
In an effort to standardize the sample population of subjects for this investigation, it was 
essential that subjects be carefully screened for any atypical condition. Therefore, in 
addition to satisfying the above criteria, subjects must have had a complete ocular 
examination in the last 12 months to ensure that none of the contraindications described 
below applied before being considered eligible to participate in this study. 
Exclusion Criteria 
No subject was entered into this study who was known to have or currently exhibit any of 
the following conditions: 
1. Ocular or systemic allergies which might interfere with contact lens wear. 
2. Systemic disease or use of medication which might interfere with contact lens wear. 
3. Clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal 
staining, bulbar hyperemia, tarsal hyperemia or any other abnormality of the cornea 
which might cause unsafe contact lens wear. 
4. Any active ocular infection or ocular surface disease. 
5. Any corneal distortion resulting from previous hard contact lens wear. 
6. Pregnancy or lactation. 
Informed Consent 
If the subject was deemed eligible, the investigators or monitor explained in detail the 
nature of the study and the subject's requirements for participation in the two-month 
study. Interested subjects were asked to read the Statement of Informed Consent Form 
and the principal investigators and/or the study monitor answered any and all questions. 
All participants were required to sign both copies of the Statement of Informed Consent 
Form and were provided a copy of the consent form. 
Ocular Examination 
Candidates for this study were screened from the outpatient clinic at Pacific University 
College of Optometry in Forest Grove, Oregon. All candidates for the study were 
required to have undergone a complete, dilated ocular examination within the past 12 
months. Subject eligibility was established at the Enrollment Visit Examination and a 
total of 30 subjects were selected. The subjects were required to meet all of the 
previously described inclusion criteria to be considered eligible for this study. 
A modified ocular examination was performed at the Enrollment Visit. The examination 
included the following: 
detailed patient history 
slit lamp examination, including NaFl evaluation 
habitual silicone hydrogel contact lens fit evaluation with the slit-lamp 
habitual contact lens spherical over-refraction 
Lens Dispensing 
Eligible subjects were dispensed a new pair of lenses in the most appropriate lens 
parameters based on the lens-fit evaluation and over-refraction. 
Study Lens Parameters 
Silicon Hydrogel Contact Lenses: Base Curves: 8.4 and 8.6 mm 
Powers : +6.00 D to -10.00 D. 
Diameter: 13.8 mm 
Detailed oral and written instructions were given to each subject describing the study 
requirements. 
Subjects were instnlcted to: 
wear the same pair of lenses throughout the course or each study phase 
return for regularly scheduIed follow-up visits 
immediately report any abnormalities, e.g., ocular complications, lost or 
uncomfortable lenses to the investigators or monitors 
* instill the lens drops three times a day in both eyes 
refrain from instilling a lens drop within one hour before scheduled study visits 
Adverse Reactions and Discantinuations 
Subjects were instructed that if they experienced ocular irritation or disturbance of vision, 
they should contact the investigator or monitor on-call for the study. Three subjects did 
not complete all phases. Two subjects dropped out in the first two week session as they 
were not comfortable with the silicone I~ydrogel contact lenses. The third contracted an 
upper respiratory infection between the first and second month phases, and was 
discontinued due to this unrelated illness. 
If for any reason a lens needed to be removed, subjects were instructed to rinsed it for a 
minimum of 10 seconds with saline and then reinsert. 
Two-Week Follow-Up Visit 
For both Period 1 and Period 2, at the two-week and one-month follow-up visits the 
subjects completed subjective questionnaires assessing: comfort and lens-awareness 
symptoms with the initial lens drops. 
An investigator masked to the type of lens drops the subject was using performed an 
examination that included the following: 
distance visual acuity 
* near visual acuity 
slit-lamp examination including surface deposit assessment and grading of posterior 
debris (number of mucin balls) 
- spherical over-refraction in phoropter if indicated by entrance visual acuity 
Phase IT, Lens Drop Crossover 
At t l~c ompletion of the one-month visit each subject completed a three-day "wash-out" 
period as previously described and was dispensed a new pair of Focus Night and Day 
lenses. I'he subjects were once again given dctailed oral and written instructions on the 
wearing of the contact lenses, 
Subjects were instructed to: 
wear the same pair of lenses throughout the course of the month 
return for regularly scheduled follow-up visit one month later 
immediately report any abnormalities, e.g., ocular complications, lost or damaged 
lenses, to the investigators or monitor. 
* instill the lens drops three times a day En both eyes 
Along with standard one-rnonth assessme~~ts, at the final visit subjects were then asked to 
complete an additional overaII Iens drop preference survey. 
Subject participation in thc study concluded after completion of the two-rnontll visit. 
Results 
Data Analysis 
Statistical Method 
This study followed a 2x2 cross over design in which subjects were randomly assigned to 
in-eye cleaninglre-wetting drops (indicated in these analyses as " G )  or re-wetting drops 
("W). Due to the cross over design it was important to consider possible time and carry- 
over effects. A carry -over effect was not considered to be too great a concern due to the 
nature of the treatments, but was tested for nevertheless. 
Time deserves careful consideration, as it is possible that ratings of comfort will be 
affected by adaptation to the lens wear. 
Subjects were asked to rate comfort on a 100 point scale at each visit. They were asked 
to rate the comfort upon awakening, during the day, and in the evening before retiring. 
Higher scores indicate better comfort. We considered ratings of comfort obtained for 
three time-of-day categories: Upon awakening (AM), throughout the day (DAY) and in 
the late evening (EVE). 
Analysis of comfort data was performed using NCSS Statistical Software (329 North 
1000 East . Kaysville, Utah, 84037). The data were entered into three variables. The first 
variable contains the sequence number. For these analyses sequence " 1" was used for 
subjects having the " G  drops in the first phase (order is GW) and the " W  in the second. 
"2" was used to indicate those using the " W  drops in the first phase (order WG). The 
second variable contains the response in the first phase, and the third variable contains 
the response in the second phase. Thus, each row of data represented the complete 
response for a singIe subject. 
Cross over design analysis is designed to test primarily for equivalence. If ecluivalence is 
rejected, we can test further for relative superiority or inferiority. 
We have choscn for analysis the responses at the end of each phase as it was felt these 
would best reflect the efficacy of the testcd articles. 
AM Comfort 
Cross-Over Analysis Summary Section: AM Comfort 
Lower 95.0% Upper 95.0% 
Estimated Standard T Value Prob Confidence Confidence 
Parameter Effect Error @F=24) Level Limit Limit 
Treatment -2.43 4.09 -0.59 0.5587 -10.88 6.02 
Period 12.02 4.09 2.93 0.0072 3.57 20.47 
Carryover 4.44 18.48 0.24 0.8123 -33.70 42.58 
Interpretation of the Above Report 
The two treatment means in this 2x2 cross-over study are not significantly different at the 0.0500 
significance level (the actual significance level was 0.5587). The average response to treatment 
G was 54.88 and the average response to treatment W was 52.45. 
A preliminary test rejected the assumption of equal period effects at the 0.0500 significance level 
(the actual significance Ievel was 0.0072). A preIiminary test failed to reject the assumption of 
qua1  carryover effects at the 0.0500 significance Ievel (the actual significance level was 0.8123). 
Cross-Over Anaiysis Detail Section: AM Comfort 
Least Squares 
Seq. Period Treatment Count Mean 
1 1 G 17 47.76 
2 2 G 9 62.00 
I 2 W 17 57.35 
2 1 W 9 47.56 
1 Difference (W-G)/2 17 4.79 
2 Difference (W-Cr)D 9 7.22 
1 Total G-I-W 17 105.12 
2 Total W W  9 109.56 
G 26 54.88 
W 26 52.45 
1 34 52.56 
2 18 54.78 
1 26 47.66 
2 26 59.68 
Standard 
Deviation 
27.42 
19.07 
27.20 
16.12 
8.82 
11 -85 
51.69 
26.16 
Standard 
Error 
6.65 
6.36 
6.60 
5.37 
2.14 
3.95 
12.54 
8.72 
5.14 
4.96 
Interpretation of the Above Report 
This report shows the means and standard deviations of various subgroups of the data. The least 
squares mean of treatment G is 54.88 and of treatment W is 52.45. Note that least squares means 
are created by taking the simple average of their component means, not by taking the average of 
the raw data. No adjustment is made for the unequal sample sizes. 
Equivalence Based on the Confidence Interval of the Difference: AM Comfort 
Lower Lower 90.0% Upper 90.0% Upper Equivalent 
Equivalence Confidence Confidence Equivalence at the 5.0% 
Test Type Limit Limit Limit Limit Sign. Level? 
Shortest C.I. -10.98 -9.43 4.58 10.98 Yes 
Westlake C.I. -10.98 -8.05 8.05 10.98 Yes 
Note: Westlake's k2 = -1.37 and k l  = 2.56. 
Interpretation of the Above Report 
Average bioequivalence of the two treatments has been found at the 0.0500 significance level 
using the shortest confidence interval of the difference approach since both confidence limits, 
-9.43 and 4.58, are between the acceptance limits of -10.98 and 10.98. 
Average bioequivalence of the two treatments has been found at the 0.0500 significance level 
using Westlake's co
nfi
dence interval of the difference approach since both confidence limits, 
-8.05 and 8.05, are between the acceptance limits of -10.98 and 10.98. 
Equivalence Based on the Confidence Interval of the Ratio: AM Comfort 
Lower Lower 90.0% Upper 90.0% Upper Equivalent 
Equivalence Confidence Confidence Equivalence at the 5.0% 
Test Type Limit Limit Limit Limit Sign. Level? 
Shortest C.I. 80.00 82.81 108.34 120.00 Yes 
Westlake C.I. 80.00 85.34 114.66 120.00 Yes 
Fieller's C.I. 80.00 83.03 109.74 120.00 Yes 
Interpretation of the Above Report 
Average bioequivalence of the two treatments has been found at the 0.0500 significance level 
using the shortest confidence interval of the ratio approach since both confidence limits, 82.8 1 
and 108.34, are between the acceptance limits of 80.00 and 120.00. 
Average bioequivalence of the two treatments has been found at the 0.0500 significance level 
using Westlake's confidence interval of the ratio approach since both confidence limits, 85.34 
and 1 14.66, are between the acceptance limits of 80.00 and 120.00. 
Average bioequivalence of the two treatments has been found at the 0.0500 significance level 
using Fieller's confidence interval of the ratio approach since both confidence limits, 83.03 and 
109.74, are between the acceptance limits of 80.00 and 120.00. 
Equivalence Based on Schuirmann's Two One-Sided Hypothesis Tests: AM Comfort 
Lower Upper 5.0% Equivalent 
Test Test Cutoff at the 5.0% 
Test Type T Value T Value T Value DF Sign. Level? 
Schuirmann's 2 1 -Sided Tests 2.09 -3.27 1.71 24 Yes 
Interpretation of the Above Report 
Average bioequivalence of the two treatments was found at the 0.0500 significance level using 
Schuinnann's two one-sided t-tests procedure. The probability level of the t-test of whether the 
treatment mean is not too much lower than the reference mean is 0.0238. The probability level of 
the t-test of whether the treatment mean is not too much higher than the reference mean is 
0.0016. Since both of these values are less than 0.0500, the null hypothesis of average 
bioinequivalence was rejected in favor of the alternative hypothesis of average bioequivalence. 
Equivalence Based on Two One-Sided Wilcoxon-Mann-Whitney Tests: AM Comfort 
Lower Lower Upper Upper Equivalent 
Sum Prob Sum Prob at the 5.0% 
Test Type Ranks Level Ranks Level Sign. Level? 
2 1-Sided MW Tests 265.00 0.0295 177.00 0.0025 No 
Interpretation of the Above Report 
Average bioequivalence of the two treatments was not established at the 0.0500 significance 
level using the nonparametric version of Schuirmann's two one-sided tests procedure which is 
based on the Wilcoxon-Mann-Whitney test. The probability level of the test of whether the 
treatment mean is not too much lower than the reference mean is 0.0295. The probability level of 
the test of whether the treatment mean is not too much higher than the reference mean is 0.0025. 
Since at least one of these values is greater than 0.0500, the null hypothesis of  average 
bioinequivalence was not rejected. 
Equivalence Based on Anderson and Hauck's Hypothesis Test: AM Comfort 
Equivalent 
Prob at the 5.0% 
Pr(-TL) Pr(TU) Level Sign. Level? 
0.0238 0.00 16 0.0222 Yes 
Test Type 
Anderson and Hauck's Test 
Interpretation of the Above Report 
Average bioequivalence of the two treatments was found at the 0.0500 significance IeveI using 
Andcrsan and Hauck's test procedure. The actual probability level of the test was 0.0222. 
Plot of Sequence-by-Period Means: AM Comfort 
Sequence-by-Period Means 
Treatment 
0 G 
W 
45.00 
Awakenin Awakenin 
Period 
Interpretation o f  the Sequence-by-Period Means 
The sequence-by-period means plot shows the mean responses on the vertical axis and the 
periods on the horizontal axis. The lines connect like treatments. If there is no period, carryover, 
or interaction effects, two horizontal lines would be displayed. The distance between these lines 
represents the magnitude of the treatment effect. The tendency for both lines to slope up 
represents period and carryover effects. Tile fact that the lines do not cross represents absence of 
period-by-treatment interaction, a type of carryover effect. 
Plot of Subject Profiles: AM Comfort 
Subject Profile Plot 
- 
I I I I 1 
1G I W  2G 2W 
Sequence and Treatment 
Interpretation of the Profile Plot- 
The profile plot displays the raw data for each subject. The response variable is shown along the 
vertical axis. The two sequences are shown along the horizontal axis. The data for each subject is 
depicted by two points connected by a line. The subject" response to the reference formulation is 
shown first followed by their response to the treatment formulation. Hence, for sequence 2, the 
results for the first period are shown on the right and for the second period on the left. 
Plot of Sums and Differences: AM Comfort 
Sum Difference Plot 
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Interpretation of  the Sums and Differences Plot 
The sums and differences plot shows the sum of each subject's two responses on the horizontal 
axis and the difference between each subject's two responses on the vertical axis. Dot plots of the 
sums and differences have been added above and to the right of the scatter plot, respectively. 
Each point represents the sum md difference of a single subject. Different plotting symbols are 
used to denote the subjects sequence. A horizontal line has been added at zero to provide an easy 
reference from which to determine i fa  difference is positive (favors treament G )  or negative 
(favors treatment W), The degrce to which the plotting symbols tend to separate along the 
horizontal axis represents the size of the carryover effect, The degree to which the plotting 
symbols tend to separate along the vertical axis represents the size of the treatment effect. 
Period Plot: AM Comfort 
Period Plot 
1 Sequence 
Awakeningx 
Interpretation of the Period Plot 
The Period Plot displays a subject's period 1 response on the horizontal axis and their period 2 
response on the vertical axis. The plotting symbol is the sequence number. 
Probability Plots: AM Comfort 
Normal Probability Plot of Seq 1 Differences Normal Probability Plot of Seq 2 Differences 
20.0- 
0.0 
-20.0- 
4 . 0 .  
-60.0?, 
-2.0 -1 .O 0.0 1 .O 20 -1.5 -0.8 0.0 0.8 1.5 
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Interpretation of the Probability Plots 
These plots show the differences (PI-P2) on the vertical axis and values on the horizontal axis 
that would be expected if the differences were normally distributed. The first plot shows the 
differences for sequence 1 and the second plot shows the differences for sequence 2. The 
assumption of normality holds, as the points fall close to a straight line. 
DAY Comfort 
Cross-Over Analysis Summary Section: DAY Comfort 
Lower 95.0% Upper 95.0% 
Estimated Standard T Value Prob Confidence Confidence 
Parameter Effect Error (DF=24) Level Limit Limit 
Treatment 0.99 2.49 0.40 0.6944 -4.15 6.13 
Period 7.66 2.49 3.07 0.0052 2.52 12.80 
Carryover -9.39 12.85 -0.73 0.4719 -35.91 17.13 
Interpretation of the Above Report 
The two treatment means in a 2x2 cross-over study are not significantly different at the 0.0500 
significance level (the actual significance level was 0.6944). The design had 17 subjects in 
sequence 1 (GW) and 9 subjects in sequence 2 (WG). The average response to treatment G was 
7 1.19 and the average response to treatment W was 72.1 8. 
A preliminary test rejected the assumption of equal period effects at the 0.0500 significance level 
(the actual significance level was 0.0052). A preliminary test failed to reject the assumption of 
equal carryover effects at the 0.0500 significance Ievel (the actual significance level was 0.471 9). 
Cross-Over Analysis Detait Section: DAY Comfort 
Seq. 
1 
Period 
1 
Difference 
Difference 
Total 
Totd 
Least Squares 
Treatment Count Mean 
G 17 69,71 
G 9 72.67 
W 17 78.35 
W 9 66.00 
(W-G)/2 17 4.32 
(W-G)/2 9 3.33 
G+W 17 148.06 
W W  9 13 8.47 
G 26 71.19 
W 26 72.18 
34 74.03 
18 69.33 
26 67.85 
26 75.51 
Standard 
Deviation 
17.54 
17.28 
14.82 
17.98 
6.15 
5.81 
30.05 
33.30 
Standard 
Error 
4.25 
5.76 
3.60 
5.99 
1.49 
1.94 
7.29 
11.10 
3.60 
3.29 
Interpretation of the Above Report 
This report shows the means and standard deviations of various subgroups of the data. The least 
squares mean of hcatment G is 71.19 and of treatment W is 72.1 8. Note that least squares means 
are created by taking the simple average of their component means, not by taking the average of 
the raw data. 
Equivalence Based on the Confidence Interval of the Difference: DAY Comfort 
Lower Lower 90.0% Upper 90.0% Upper Equivalent 
Equivalence Confidence Confidence Equivalence at the 5.0% 
Test Type Limit Limit Limit Limit Sign. Level? 
Shortest (2.1. -14,24 -3.27 5.25 14.24 Yes 
Westlake C.I. -14.24 -4.56 4.56 14.24 Yes 
Note: Westlake's k2 = -2.23 and kl  = 1.43. 
Interpretation of the Above Report 
Avcrage bioequivaIence of the two treatments has been found at the 0,0500 significance level 
using the shortest confidence interval of the difference approach since both confidence limits, - 
3.27 and 5.25, are between the acceptance limits of -14.24 and 14.24. 
Average bioequivalence of the two treatments has been found at the 0.0500 significance level 
using Westlake's confidence intervaI of the difference approach since both confidence limits, - 
4.56 and 4.56, are between the acceptance limits of -14.24 and 14.24. 
Equivalence Based on the Confidence Interval of the Ratio: DAY Comfort 
Lower Lower 90.0% Upper 90.0% Upper Equivalent 
Equivalence Confidence Confidence Equivalence at the 5.0% 
Test Type Limit Limit Limit Limit Sign. Level? 
Shortest C.I. 80.00 95.41 107.38 120.00 Yes 
Westlake C.I. 80.00 93.59 106.41 120.00 Yes 
Fieller's C.I. 80.00 94.62 108.67 120.00 Yes 
Interpretation of the Above Report 
Average bioequivalence of the two treatments has been found at the 0.0500 significance level 
using the shortest confidence interval of the ratio approach since both confidence limits, 95.41 
and 107.38, are between the acceptance limits of 80.00 and 120.00. 
Average bioequivalence of the two treatments has been found at the 0.0500 significance level 
using Westlake's confidence interval of the ratio approach since both confidence limits, 93.59 
and 106.41, are between the acceptance limits of 80.00 and 120.00. 
Average bioequivalence of the two treatments has been found at the 0.0500 significance level 
using Fieller's confidence interval of the ratio approach since both confidence limits, 94.62 and 
108.67, are between the acceptance limits of 80.00 and 120.00. 
Equivalence Based on Schuirmann's Two One-Sided Hypothesis Tests: DAY Comfort 
Lower Upper 5.0% Equivalent 
Test Test Cutoff at the 5.0% 
Test Type T Value T Value T Value DF Sign. Level? 
Schuirmann's 2 1 -Sided Tests 6.11 -5.32 1.71 24 Yes 
Interpretation of the Above Report 
Average bioequivalence of the two treatments was found at the 0.0500 significance level using 
Schuirmann's two one-sided t-tests procedure. The probability level of the t-test of whether the 
treatment mean is not too much lower than the reference mean is 0.0000. The probability level of 
the t-test of whether the treatment mean is not too much higher than the reference mean is 
0.0000. Since both of these values are less than 0.0500, the null hypothesis of average 
bioinequivalence was rejected in favor of the alternative hypothesis of average bioequivalence. 
Equivalence Based on Two One-Sided Wilcoxon-Mann-Whitney Tests: DAY Comfort 
Lower Lower Upper Upper Equivalent 
Sum Prob Sum Prob at the 5.0% 
Test Type Ranks Level Ranks Level Sign. Level? 
2 1 -Sided MW Tests 302.00 0.0001 163 .OO 0.0002 Yes 
Interpretation of the Above Report 
Average bioequivalence of the two treatments was found at the 0.0500 significance level using 
the nonparametric version of Schuirmann's two one-sided tests procedure which is based on the 
Wilcoxon-Mann-Whitney test. The probability level of the test of whether the treatment mean is 
not too much lower than the reference mean is 0.0001. The probabiIity level of the test of 
whether the treatment mean is not too much highcr than the reference mean is 0.0002. Since both 
of these values are Icss than 0.0500, the null hypothesis of average bioincquivalence was rejected 
in favor of the alternative hypothesis of average bioequivalence. 
Equivalence Based on Anderson and Hauck's Hypothesis Test: DAY Comfort 
Equivalent 
Prob at the 5.0% 
Level Sign. Level? 
0.0000 Yes 
Test Type 
Anderson and IIauck's Test 
Interpretation of the Above Report 
Average bioequivalcnce of the two treatments was found at the 0.0500 significance level using 
Anderson and Fiauck's test procedure. The actual probabiIity Icvel of the test was 0.0000. 
Plot of Sequence-by-Period Means: DAY Comfort 
Sequence-by-Period Means 
Treatment 
0 G 
A W  
66.00 
Daytirnex Daytimex 
Period 
Interpretation of the Sequence-by-Period Means 
The sequence-by-period mcans plot shows the mean responses on the vertical axis and Ihe 
periods on the horizontal axis. The lines connect like treatments. If  there is no period, carryover, 
or interaction effects, two horizontal lines would be displayed. The distancc between these lines 
represents the magnitude of the treabnent effect. The fact that both lines dope up represents 
likely period or carryover effects. The fact that the lines cross suggests period-by-treatment 
interaction, a type of carryover effect. 
Plot of Subject Profkes: DAY Comfort 
Subject Profile Plot 
Sequence and Treatment 
Interpretation of the Profile PIot 
The profile plot displays the saw data For each subject. The response variable is shown along the 
vertical axis. The two sequences are shown along the horizotlt~ll axis. The data for each subject is 
depicted by two points connected by n line, The subject" response to the reference formulation is 
shown first followed by their response to the treatment formulation. Hence, for sequence 2, the 
results for the first period are shown on the right and for the second period on the left. 
Plot of Sums and Differences: DAY Comfort 
Sum Difference Plot 
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Interpretation of the Sums and Differences Plot 
The sums and differences plot shows the sum of each subject's two responses on the horizontal 
axis and the difference between each subject's two responses on the vertical axis. Dot plots of the 
sums and differences have been added above and to the right of the scatter plot, respectively. 
Each point represents the sum and difference of a single subject. Different plotting symbols are 
used to denote the subject's sequence. A horizontal line has been added at zero to provide an easy 
reference fiom which to determine if a difference is positive (favors treatment G) or negative 
(favors treatment W). The degree to which the plotting symbols tend to separate along the 
horizontal axis represents the size of the carryover effect. The degree to which the plotting 
symbols tend to separate along the vertical axis represents the size of the treatment effect. 
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Period Plot: DAY Comfort 
Period Plot 
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Interpretation of the Period Plot 
The Period Plot displays a subject's period 1 response on the horizontal axis and their period 2 
response on the vertical axis. The plotting symbol is the sequence number. 
Probability Plots: DAY Comfort 
Normal Probability Plot of Seq 1 Differences 
Expected Normals 
Normal Probability Plot of Seq 2 Differences 
Expected Normals 
Interpretation of the Probability Plots 
These plots show the differences 81-P2) on the vertical axis and values on the horizontal axis 
that would be expected if the differences were normally distributed. VIC first plot shows the 
differences for sequence I and the second plot shows the differences for sequence 2. The 
assumption of normality holds, as the points fall close to a straight line. 
EVE Comfort 
Cross-Over Analysis Summary Section: EVE Comfort 
Lower 95.0% Upper 95.0% 
Estimated Standard T Value Prob Confidence Confidence 
Parameter Effect Error (DF=24) Lcvel Limit Limit 
Treatment 4.83 3.23 1 .SO 0.1477 -1.83 1 1.49 
Period 3.94 3.23 1.22 0.2342 -2.72 10.60 
Carryover -1 7.03 15.61 -1.09 0.2861 -49.23 15.18 
Interpretation o f  the Above Report 
The two treatment means in a 2x2 cross-over study are not significantIy different at the 0.0500 
significance IeveI (the actual significance level was 0.1477). The treatment order designated 
sequence 1 (GW) and 9 subjects in sequence 2 (WG). The average response to treatment G was 
60.07 and the average response to treatment W was 64.89. 
A preliminary test failed to reject the assumption of equal period effects at the 0.0500 
significance Ievel (the actual significance level was 0.2342). A preIiminary test failed to 
reject the assumption of equal carryover effects at the 0.0500 significance level (the actual 
significance level was 0.2861). 
Cross-Over Analysis Detail Section: EVE Comfort 
Seq. 
Difference 
Difference 
Total 
Least Squares 
Treatment Count Mean 
G 17 62.35 
G 9 57.78 
W 17 71.12 
W 9 58.67 
(W-G)/2 17 4-38 
(W-G)/2 9 -0.44 
G-t-W 17 133.47 
G+W 9 1 16.44 
G 26 60.07 
W 26 64.89 
34 66.74 
18 58.22 
26 60.5 1 
26 64.45 
Standard 
Deviation 
22.12 
24.32 
18.31 
2 6.64 
9.01 
4.63 
36.39 
40.64 
Standard 
Error 
5.36 
8.1 1 
4.44 
5.55 
2.19 
1.54 
8.82 
13.55 
4.71 
3.66 
Interpretation of the Above Report 
This repofl shows the means and standard deviations of various subgroups of the data. The least 
squares mean of treatment G i s  60.07 and of treatment W is (4.89. Note that least squares means 
are created by taking the simple average of their component means, not by taking the average of 
the raw data. No ad-justment is made for the unequal sample sizes. 
Equivalence Based on the Confidence Interval of the Difference: EVE Comfort 
Lower Lower 90.0% Upper 90.0% Upper Equivalent 
Equivalence Confidence Confidence Equivalence at the 5.0% 
Test Type Limit Limit Limit Limit Sign. Level? 
Shortest C.I. -12.01 -0.69 10.35 12.01 Yes 
Westlake C.I. -12.01 -9.08 9.08 12.01 Yes 
Note: WcstlaZcets k2 = -4.3 1 and kl = 1.32. 
Interpretation of  the Ahove Report 
Average bioequivalence of the two treatments has been found at the 0.0500 significance level 
using the shortest confidence interval of the difference approach since both confidence limits, - 
0.69 and E 0.35, are between the acceptance limits o f  -1 2.01 and 12.01. 
Average biocquivalence of the two i~eatments has been found at the 0.0500 significance level 
using Westlake's confidence interval of the difference approach since both confidence limits, - 
9.08 and 9.08, are between the acceptance limits of -1 2.01 and 12.01. 
Equivalence Based on the Confidence Interval of the Ratio: EVE Comfort 
Lower Lower 90.0% Upper 90.0% Upper Equivalent 
Equivalence Confidence Confidence Equivalence at the 5.0% 
Test Type Limit Limit Limit Limit Sign. Level? 
Shortest C.I. 80.00 98.84 1 17.23 120.00 Yes 
Westlake C.I. 80.00 84.88 115.12 120.00 Yes 
Fieller's C.I. 80.00 95.80 122.16 120.00 No 
Interpretation of the Above Report 
Average bioequivalence of the two treatments has been found at the 0.0500 significance level 
using the shortest confidence interval of the ratio approach since both confidence limits, 98.84 
and 117.23, are between the acceptance limits of 80.00 and 120.00. 
Average bioequivalence of the two treatments has been found at the 0.0500 significance level 
using Westlake's confidence interval of the ratio approach since both confidence limits, 84.88 
and 115.12, are between the acceptance limits of 80.00 and 120.00. 
Average bioequivalence of the two treatments has not been established at the 0.0500 
significance level using Fieller's confidence interval of the ratio approach since both 
confidence limits, 95.80 and 122.16, are not between the acceptance limits of 80.00 and 120.00. 
Equivalence Based on Schuirmann's Two One-Sided Hypothesis Tests 
Lower Upper 5.0% Equivalent 
Test Test Cutoff at the 5.0% 
Test Type T Value T Value T Value DF Sign. Level? 
Schuirmann's 2 1-Sided Tests 5.22 -2.23 1.71 24 Yes 
Interpretation of the Above Report 
Average bioequivalence of the two treatments was found at the 0.0500 significance level using 
Schuirmann's two one-sided t-tests procedure. The probability level of the t-test of whether the 
treatment mean is not too much lower than the reference mean is 0.0000. The probability level of 
the t-test of whether the treatment mean is not too much higher than the reference mean is 
0.0178. Since both of these values are less than 0.0500, the null hypothesis of average 
bioinequivalence was rejected in favor of the alternative hypothesis of average bioequivalence. 
Equivalence Based on Two One-Sided Wilcoxon-Mann-Whitney Tests: EVE Comfort 
Lower Lower Upper Upper Equivalent 
Sum Prob Sum Prob at the 5.0% 
Test Type Ranks Level Ranks Level Sign. Level? 
2 1-Sided MW Tests 303.00 0.0000 192.00 0.0230 Yes 
Interpretation of the Above Report 
Average bioequivalence of the two treatments was found at the 0.0500 significance level using 
the nonparametric version of Schuirmann's two one-sided tests procedure which is based on the 
Wilcoxon-Mm-Whihey test. The probability level of the test of whether the treatment mean is 
not too much lower than the reference mean is 0.0000, The probability level of the test of 
whether the treatment mean is not too much higher than the reference mean is 0.0230. Since both 
of these values are less than 0.0500, the nu11 hypothesis o f  average bioinequivalence was rejected 
in favor of the alternative hypothesis of average bioequivalence. 
Equivalence Based on Anderson and Hauck's Hypothesis Test 
Test Type 
Anderson and T-Iauck's Test 
Equivalent 
Prob at the 5.0% 
Level Sign. Level? 
0.0178 Yes 
Interpretation of the Above Report 
Average bioequivalence of the two treatments was found at the 0.0500 significance level using 
Anderson and I-lauck's test procedure. The actual probability level of the test was 0.0 178. 
Plot of Sequence-by-Period Means 
Sequence-by-Period Means 
Treatment 
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Tnterpretatian of the Sequence-by-Period Means 
The sequence-by-period means plot shows the mean responses on the vertical axis ancl the 
periods on the horizontal axis. The lines connect like treatments. If there is no period, carryover, 
or interaction effects, two horizontal Iines would be displayed. The distance between these lines 
represents t l~c magnitude of the treatment effect. The ract that both lines slope up represents 
Iikely period or carryover effects. The fact that the lints cross suggests period-by-treatment 
interaction, a type of carryover effect. 
Plot of Subject Profiles: EVE Comfort 
Subject Profile Plot 
Sequence and Treatment 
Interpretat ion of the Profile Plot 
The profile plot displays h e  raw data for each subject. The response variable is shown along the 
vertical axis. The two sequences are shown along the horizontal axis. The data for each subject is 
depicted by two points connected by a line. The subject's response to the reference formulation is 
shown fust followed by their response to the treatment formulation. Hence, for sequence 2, the 
results for the first period are shown on the right and for the second period on the left. 
Plot of Sums and Differences: EVE Comfort 
Sum Difference Plot 
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Interpretation of the Sums and Differences Plot 
The sums and differences plot shows the sum of each subject's two responses on the horizontal 
axis and the difference between each subject's two responses on the vertical axis. Dot plots of the 
sums and differences have been added above and to the right of the scatter plot, respectively. 
Each point represents the sum and difference of a single subject. Different plotting symbols are 
used to denote the subject's sequence. A horizontal line has been added at zero to provide an easy 
reference from which to determine if a difference is positive (favors treatment G) or negative 
(favors treatment W). The degree to which the plotting symbols tend to separate along the 
horizontal axis represents the size of the carryover effect. The degree to which the plotting 
symbols tend to separate along the vertical axis represents the size of the treatment effect. 
Period Plot: EVE Comfort 
Period Plot 
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Interpretation of the Pcriod Plot 
The Period Plot displays a subject's period 1 response on the horizontal axis and thcir period 2 
response on the vcrticd axis. The plotting symbol is the sequence number. 
Probability Plots: EVE Comfort 
Normal Probability Plot of Seq 1 Differences 
40.0, 
Expetled Normals 
Normal Probability Plot of Seq 2 Differences 
-1.5 -0.8 0.8 1.5 
Expected Normals 
Tntcrpretation of the Probability Plots 
These plots show the differences (Pl-P2) on the vertical axis and values on the horizontal axis 
that would be expected if the differences were nomaIIy distributed. Tlie first plot shows the 
differences for sequence 1 and the second plot shows ihe differences for sequence 2. The 
assumption of normality holds, as the points fall close to a straight line. 
Subjects 
Twenty seven subjects completed both phases of the study. Two subjects were 
discontinued secondary to lens awareness or discomfort with the study contact lenses and 
one subject lost a lens from the eye during sleep and was also suffering from an upper 
respiratory infection. Data was considered only from the subjects completing all phases. 
Subject age ranged f m  21-52 years and refractive error ranged from +3.00 D to -6.00 D. 
Ten males and 20 fernaIes participated in the study. 
Habitual Lens Drops 
Prior to study enrollment 7 subjects habitually used lens drops. 
Objective Findings 
Biomicroscope Examination and Adverse Events 
A biomicroscope examination was performed at each visit using a 0-4 scale for each 
observalion. A copy of the examination form is attached. None of thc biomicroscopy 
scores showed a difference between the two types of drops at my point or in either phase. 
No adverse responses occurred during the study. 
Visual Acuity 
No statistical or clinical difference in visuaI acuity between lens drops was observed at 
any point. 
On-Eye Surface Deposition and Wetting 
No clinical or statistical difference could be detected in the grading of rront surface 
wetting, front surface deposits, posterior lens debris or number of mucin balls. 
Lenses were collected at the completion of each four week interval and have been sent to 
the CCLR at the University of Waterloo for laboratory analysis. 
Comfort and Awareness: Evidence of  Adaptation, Change with time 
Comfort and awareness scores were very sirniIar and thus we chose to anaIyse the 
comfort scores in the previous section on subjective responses. We noted an apparent 
effect of adaptation, such that subjects tended to be more comfortable in the second 
phase, regardIess of drop sequence. To illustrate this, an analysis is presented using the 
Lens Awareness data, combining all subjects in each phase regardless of drops used in 
that phase. 
Lens Awareness 
Lens awareness was rated for awakening, daytime and evening at each interval. At no 
point was there a difference in awareness scores for the two drops. As with comfort 
ratings, there were changes noted with time. 
Lens Awareness Upon Awakening. 
Lens Awareness Upon Waking 
1 %-99% C.I. 
Mean 
5%-95% C.I. 
Group 
Lens awareness upon awakening, change with time 
Lens awareness upon awakening was significantly better in the second phase, regardless 
of drop type (p<0.01 comparing the 2 week of the second phase to either interval in the 
first phase. p<0.05 comparing the 4 week visit of the second phase to the 4 week interval 
in phase one). Note the only baseline data was obtained prior to phase one. 
Lens Awareness During the Day 
Lens awareness during the day was different ('<0.01) from other intervals and baseline 
only at the 4 week interval of the first phase. 
Lens Awareness Daytime 
71 - 
1 
--- I '  
1"i - 
- 
57 
f- T 1%-99% C.I. Mean 
5%-95% C.I. 
Group 
Lens awareness Daytime, change with time 
Lens Awareness in the Evening 
Evening lens awareness was equal for the two drop types. There was a small but 
significant (p<0.05) difference in awareness scores for evening for both intervals of the 
first phase when compared to baseline. 
Evening Lens Awareness 
A 
-- 
II 
A 
49 - 
T 1%-99% C.I. 
Mean 
a 5%-95% C.I. 
Group 
Lens Awareness Evening, Change with time 
Sub,jective Questionaires 
Subjects responded to the following 10 questions at each of the four intervals: 
1. My lenses fecl comfortable upon awakening. 
2. My Ienses fee1 comfortable all day long. 
3. My lenses feel comfortable at the end of the day. 
4. My vision is not blurry upon awakening. 
5 ,  My eyes do not feel dry during the lens wearing day. 
6.  These drops keep my lcnses clean. 
7, Thcse drops are easy to use. 
8. I like these drops. 
9. My contact lenses feel more comfortable after the use of the drops. 
10. The drops keep my lenses clear. 
Answers were on a ranked scale of 1 (strongly disagree0 to 5 (strongly agree). 
The tablc below shows the p values for difference between the two types of drops when 
comparing the answers to each of these questions at each interval. There were no 
significant differences noted. 
----------- 
Phase 2: -76 .43 .44 .68 .69 .24 .90 .10 -06 .33 
4 week 
As changes with time had been noted in the rating scales, the questions were evaluated 
for a similar trend. Small differences were noted comparing responses at different 
intervals. No differences were noted with respect to time for questions 4, 5,7, 9 and 10. 
The differences for the other questions are depicted graphically in the next several 
figures. The "colurnn" indications from left to right indicate phase 1 :2 week ; phase 1 :4 
week; phase 2:2 week; and phase 2:4week. 
Question 1 
Mean 
5%-95% C.1 
0.70 
Column 1 Column 2 Column 3 Column 4 
Group 
Question 1 : phase 2:2 week answers differ from phase 1 :4 week answers (p<0.05) 
Question 2 
Column 1 
2:2 week Ouestion 2: ~ h m e  
Column 2 Column 3 
Group 
Column 4 
answers differ from 
Question 3 
phase 1 :4 week answers 
Column 3 Column I 3  Column 
Group 
23 Column 33 
T 1%-99% C.I. 
Mean 
0 5%-95% C.I. 
1%-99% C.I. 
Mean 
5%-95% C.I. 
Question 3: phase 2:2 week answers differ from phase 1:2 week answers (p<0.05) 
Question 6 
1.70 
Column 6 Column 16 Column 26 Column 36 
T 1%-99% C.I. 
Mean 
0 5%-95% C.I. 
Group 
Question 6: phase 2:2 week answers differ from phase 1 :2 week answers (p<0.05) 
Question 8 
Column 8 Column I 8  Column 28 Column 38 
Group 
Mean 
p1 5%-95% C.I. 
Question 8: phase 1:4 week answers differ from phase 1:2 week answers (p<0.05) 
Subject Preferences 
At the end of the study subjects were asked to respond to the following questions: 
For each of the following questions, please circle your overall preferences. 
(1) With regard to comfort, I prefer: 
a. Phase I Drops 
b. Phase I1 Drops 
c. I have no preference 
The control drop was preferred 2 to 1 over the in-eye cleaninglre-wetting drop. The 
following chart illustrates the insignificant difference between choice frequencies. " G  
indicates the in-eye cleaninglre-wetting drop. "W" indicates the control drop. 
Preference for Comfort 
% Freqtlenciesof Scores 
t .. 
W G n 
Preferred drop type 
Bivariate chi-square analysis of the responses to each question were performed in order 
to test for significance of differences and for sequence effect. The following plot 
represents the responses by phase. 
Note "Col 1" indicates indicates subjects following " G W  sequence, and "Col2" 
represents subjects in "WG" sequence. There appears to be an effect such that subjects 
tended to prefer the drop they finished with. As there were more subjects in the " G W  
Forced Choice Question1 
(Chi-Squate = 5 091969, p = 0.0784) 
- No Pref 
Prefer G 
- Prefer W 
u.u 
Col 1 Col2 
Phase 
group, this gives rise to the appearance that W was strongly preferred, when there does 
seem to be a substantial sequence effect. 
(2) With regard to vision, I prefer: 
a. Phase I Drops 
b. Phase I1 Drops 
c. I have no preference 
Preference for Vision 
% Frequencies of Scores An 7 
W n G 
Preferred drop type 
This table indicates a majority had no preference with regard to vision. 
Forced Choice Question 2 
- No Pref 
2.60 : 
I - Prefer G 
- Prefer W 
1.40 
Col 1 Col 2 
Phase 
Forced Choice Question 2: Vision 
Pref G 
No Pref 
Pref W 
Col 1 Col 2 
Sequence 
Note "Col 1" indicates indicates subjects following " G W  sequence, and "Col2" 
represents subjects in " W G  sequence. A majority had no preference regardless of 
sequence. Among those that did, there again appears to be an effect such that subjects 
tended to prefer the drop they finished with. As there were more subjects in the " G W  
group, this gives rise to the appearance that W was somewhat preferred, when there does 
seem to be a sequence effect. 
(3) With regard to lens cleanliness, I prefer: 
a. Phase I Drops 
b. Phase II Drops 
c. I have no preference 
The following table shows a preference for the control drops: 
Preference for Vision 
W G n 
Preferred drop type 
Forced Choice Question 3 
No Pref 
Prefer G 
Prefer W 
I .  IU 
Col 1 Col 2 
Phase I 
Note "Col 1" indicates indicates subjects following "GW" sequence, and "Col2" 
represents subjects in " W G  sequence. There appears to be an effect such that subjects 
tended to prefer the drop they finished with. As there were more subjects in the " G W  
group, this gives rise to the appearance that W was strongly preferred, when there does 
seem to be a substantial sequence effect. 
Discussion 
This study evaluated the subjective performance and surface characteristics of in-eye 
cleaninglre-wetting drops with continuous wear of silicone hydrogel contact lenses. In- 
eye cleaninglre-wetting drops have been shown to be beneficial in HEMA-based contact 
lenses leading to fewer surface deposits, increased wettability, and increased patient 
comfort. 
The aims of the study were: 
(1) To determine if the use of an in-eye cleaninglre-wetting drop offered better 
subjective comfort and visual perfonnance in comparison to a simple re-wetting 
drop with continuous wear of the lenses; 
(2) To determine if there is a difference in the amount and type of surface 
deposits on the lenses when using an in-eye cleaninglre-wetting drop versus a 
re-wetting drop; 
(3) To determine if there is a difference in surface wettability with the use of an 
in-eye cleaninglre-wetting drop versus a re-wetting drop with continuous 
wear of the lenses. 
We were unable to detect any difference in subjective comfort or lens awareness for the 
two drops tested. Overall comfort scores were quite good, although two subjects dropped 
out due to inability to achieve acceptable comfort with the lenses. This appeared to be 
much more of a lens related issue than anything related to the drops. 
A trend towards decreased comfort and increased lens awareness with time was observed, 
particularly in the first month phase. There appeared to be evidence of adaptation in the 
second phase, where comfort and awareness were notably better at the four week visit of 
phase two than they had been at this point in phase one. This is consistent with clinical 
observation. 
The differences described above were elicited via the grading scales. Less substantial 
differences with time were noted via the questionnaire. The questionnaire also failed to 
show any difference with regard to the type of drops used. 
Observation of slit-lamp findings, and in particular on-eye observation of lens wetting, 
deposits, numbers of mucin balls were all equivalent for the two drops. In general, 
wetting and deposition were graded very favorably. No significant changes in slit-lamp 
findings were observed in either phase. 
It is to be noted that all lenses were collected at the conclusion of each phase and have 
been sent to University of Waterloo where they await analysis for any difference in 
quantity or nature of deposits. 
Conclusions 
It appears the use of in-eye cleaninglre-wetting drops is compatible with silicone 
hydrogel contact lenses worn on a 30 night continuous wear basis, and performance is 
equivalent to re-wetting drops under these circumstances. 
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